Education
About Us
Working with TipRanks
Follow Us
NeuroPace (NPCE)
NASDAQ:NPCE
NPCE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.45 - $15.11
Previous CloseN/A
Volume21.31K
Average Volume (3M)229.37K
Market Cap
$346.44M
Enterprise Value$221.90M
Total Cash (Recent Filing)$13.43M
Total Debt (Recent Filing)$73.34M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
May 08, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding32,560,130
10 Day Avg. Volume210,333
30 Day Avg. Volume229,372
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.12
Price to Cash Flow (P/CF)-54.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda-13.39
Forecast
1Y Price Target
$17.80Price Target Upside70.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
NeuroPace News
PremiumCompany Announcements
NeuroPace Shifts Focus to Core RNS System
PremiumCompany Announcements
NeuroPace, Inc. Reports Strong 2024 Growth Despite Challenges
PremiumCompany Announcements
NeuroPace Reports Strong Growth and Strategic Advancements---
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe company's ability to achieve a 20% sales growth due to a range of growth drivers, including Project CARE and planned expansion into generalized epilepsy and pediatric focal epilepsy, is promising.
Product DevelopmentManagement's confidence in the company’s brain responsive neuromodulation system (RNS) commercial operations and future expansion opportunities serves as a source of profitability improvement.
Bears Say
Cash ManagementQ4 cash burn increased to $4.8M compared to $3.4M in the previous year.
Revenue ForecastThe SEEG wind down is expected to create a headwind to total company growth in 2026, prompting a conservative decrease in the 2026 revenue estimate.
---
Ownership Overview
42.42% Insiders
5.40% Mutual Funds
17.78% Other Institutional Investors
22.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NPCE FAQ
What was NeuroPace’s price range in the past 12 months?
NeuroPace lowest stock price was $5.45 and its highest was $15.11 in the past 12 months.
What is NeuroPace’s market cap?
NeuroPace’s market cap is $346.44M.
When is NeuroPace’s upcoming earnings report date?
NeuroPace’s upcoming earnings report date is May 08, 2025 which is in 25 days.
How were NeuroPace’s earnings last quarter?
NeuroPace released its earnings results on Mar 04, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.043.
Is NeuroPace overvalued?
According to Wall Street analysts NeuroPace’s price is currently Undervalued.
Does NeuroPace pay dividends?
NeuroPace does not currently pay dividends.
What is NeuroPace’s EPS estimate?
NeuroPace’s EPS estimate is -0.24.
How many shares outstanding does NeuroPace have?
NeuroPace has 32,560,130 shares outstanding.
What happened to NeuroPace’s price movement after its last earnings report?
NeuroPace reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went down -2.433%.
Which hedge fund is a major shareholder of NeuroPace?
Currently, no hedge funds are holding shares in NPCE
---
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.80 (70.83% Upside)
$17.80 (70.83% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $49.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.16%
12-Months-Change
Fundamentals
Return on Equity
-189.35%
Trailing 12-Months
Asset Growth
-12.08%
Trailing 12-Months
Company Description
NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
---
NPCE Company Deck
---
NPCE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
NeuroPace demonstrated strong revenue growth and operational success in 2024, with significant advancements in clinical trials and product development. Despite a net loss and increased operating expenses, the company's strategic initiatives, including Project CARE and successful public offering, position it well for future growth. The overall sentiment is positive, given the successful financial and operational achievements overshadowing the financial challenges.Read More>---
NPCE Stock 12 Month Forecast
Average Price Target
$17.80
▲(70.83% Upside)
Technical Analysis
Best Analysts Covering NPCE
1 Year
1 Year Success Rate
13/21 ratings generated profit
1 Year Average Return
+46.86%
reiterated a buy rating 5 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +46.86% per trade.
---